Diagnóstico y tratamiento de la infección por el virus de la inmunodeficiencia humana, Infecciones oportunistas y trastornos relacionados. Rosa Nohemí Terán Terán

con estas dos afecciones, debe monitorearse la biometría hemática, función renal, hepática, electrolitos; y otros parámetros dependiendo del tipo de tratamiento oncológico.

      11.Se recomienda el uso de estatinas, no solo en el caso de dislipidemia, sino en todo paciente con infección por VIH que tenga factores de riesgo para cáncer.

      BIBLIOGRAFÍA

      1.Paul G. Rubinsteina, David M. Aboulafiacand AZ. Malignancies in HIV/AIDS: From Epidemiology to Therapeutic Challenges Paul. Aids. 2015;28(10):451–65.

      2.Santos J, Valencia E. Guía de práctica clínica sobre los tumores no definitorios de sida e infección por el virus de la inmunodeficiencia humana. Enferm Infecc Microbiol Clin [Internet]. 2014;32(8):515–22. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0213005X14001888

      3.Beachler DC, Abraham AG, Silverberg MJ, Jing Y, Fakhry C, Gill MJ, et al. Incidence and risk factors of HPV-related and HPV-unrelated Head and Neck Squamous Cell Carcinoma in HIV-infected individuals. Oral Oncol. 2014;50(12):1169–76.

      4.Fink VI, Jenkins CA, Castilho JL, Person AK, Shepherd BE, Grinsztejn B, et al. Survival after cancer diagnosis in a cohort of HIV-positive individuals in Latin America. Infect Agent Cancer. 2018;13(1):1–11.

      5.Powles T, Bower M, Daugaard G, Shamash J, De Ruiter A, Johnson M, et al. Multicenter study of human immunodeficiency virus-related germ cell tumors. J Clin Oncol. 2003;21(10):1922–7.

      6.Granwehr BP. Review: The impact of HIV infection on cancer treatment with immunotherapy. J Inmunoter Precis Oncol. 2019;2(3):85–92.

      7.Borges ÁH. Combination antiretroviral therapy and cancer risk. Curr Opin HIV AIDS. 2017;12(1):12–9.

      8.Zampell J, Yan A, Malliaris S, Avraham T, Weitman E, Elhadad S, et al. OPTIMAL LUNG CANCER SCREENING CRITERIA AMONG PERSONS LIVING WITH HIV. Vol. 130, Plastic and Reconstructive Surgery. Seattle, Washington; 2019. p. 20.

      9.Singal A, Volk Ml, Waljee A, Salgia R, Higgins P, Rogers MAM, et al. Meta-analysis: Surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis. Aliment Pharmacol Ther. 2009;30(1):37–47.

      10.Theo Smart. Hiv & Aids Treatment in Practice. NAM Publ. 2008;(June):1–10.

      11.Hoffmann C, Sabranski M, Esser S. HIV-Associated Kaposi’s Sarcoma. Oncol Res Treat. 2017;40(3):94–8.

      12.Johann W. Schneider and Dirk P. Dittme. Diagnosis and Treatment of Kaposi Sarcoma. Am J Clin Dermatol. 2017;18(4):529–539.

      13.Nishimura M, Watanabe T, Yagi S, Yamanaka T, Fujimuro M. Kaposi’s sarcoma-associated herpesvirus ORF34 is essential for late gene expression and virus production. Sci Rep [Internet]. 2017;7(1):1–12. Available from: http://dx.doi.org/10.1038/s41598-017-00401-7

      14.Qiwen Fang, Zhenqiu Liu, Zhijie Zhang, Yan Zeng TZ. Prevalence of Kaposi’s sarcoma-associated herpesvirus among intravenous drug users: a systematic review and meta-analysis. Virol Sin. 2017;32(5):415–22.

      15.Panel de expertos de GESIDA. RECOMENDACIONES DE GeSIDA/PETHEMA SOBRE EL DIAGNÓSTICO Y TRATAMIENTO DE LOS LINFOMAS DE PACIENTES INFECTADOS POR EL VIRUS DE LA INMUNODEFICIENCIA HUMANA Guía de [Internet]. Elsevier; [cited 2018 Feb 15]. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0213005X1300390X

      16.Ota Y, Hishima T, Mochizuki M, Kodama Y, Moritani S, Oyaizu N, et al. Classification of AIDS-related lymphoma cases between 1987 and 2012 in Japan based on the WHO classification of lymphomas, fourth edition. Cancer Med. 2014;3(1):143–53.

      17.Gupta, R. K., Abdul-Jaward,S, McCoy L et al. Spiral HIV-1 remission following CCR5Δ32-Δ32 haematopoietic stem-cell transplantation. Nat Res [Internet]. 2019;568. Available from: http://hdl.handle.net/10044/1/69028

      18.Allers K, Hutter G HJ et al. Evidence for the Cure of HIV Infection by CCR5‪32/‪32 Stem. Blood. 2011;117(10):2791–9.

      19.Jacobs EJ, Newton CC, Thun MJ, Gapstur SM. Long-term use of cholesterol-lowering drugs and cancer incidence in a large United States cohort. Cancer Res. 2011;71(5):1763–71.

      20.Chao C, Xu L, Abrams DI, Towner WJ, Horberg MA, Leyden WA, et al. HMG-CoA reductase inhibitors (statins) use and risk of non-Hodgkin lymphoma in HIV-positive persons. Aids. 2011;25(14):1771–7.

      21.Overton ET, Kitch D, Benson CA, Hunt PW, Stein JH, Smurzynski M, et al. Effect of statin therapy in reducing the risk of serious non-AIDS-defining events and nonaccidental death. Clin Infect Dis. 2013;56(10):1471–9.

      22.Ye X, Zhang G, Righolt C, Johnston JB, Banerji V, Gibson SB, et al. Associations between statin use and risk of non-Hodgkin lymphomas by subtype. Int J Cancer. 2018;143(4):971–9.